These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31078666)

  • 1. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
    Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
    Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
    Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW
    Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
    van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
    Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
    van der Aart-van der Beek AB; Apperloo E; Jongs N; Rouw DB; Sjöström CD; Friedli I; Johansson L; van Raalte DH; Hoogenberg K; Heerspink HJL
    Diabetes Obes Metab; 2023 Jun; 25(6):1758-1768. PubMed ID: 36843215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Wexler DJ; de Boer IH; Ghosh A; Younes N; Bebu I; Inzucchi SE; McGill JB; Mudaliar S; Schade D; Steffes MW; Tamborlane WV; Tan MH; Ismail-Beigi F;
    JAMA Intern Med; 2023 Jul; 183(7):705-714. PubMed ID: 37213109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
    Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
    Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lilly Insulin Glargine Versus Lantus
    Mohan V; Ahn KJ; Cho YM; Sahay RK; Huang CN; Kalra S; Chadha M; Bhattacharya I; Kim SY; Spaepen E
    Clin Drug Investig; 2019 Aug; 39(8):745-756. PubMed ID: 31119716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
    Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
    Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
    Cai TT; Li HQ; Jiang LL; Wang HY; Luo MH; Su XF; Ma JH
    Biomed Res Int; 2021; 2021():3361309. PubMed ID: 34580638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
    Cherney DZI; Heerspink HJL; Frederich R; Maldonado M; Liu J; Pong A; Xu ZJ; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
    Diabetologia; 2020 Jun; 63(6):1128-1140. PubMed ID: 32236732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.